MCS-2

DRUG3 trials

Sponsors

Health Ever Bio-Tech Co., Ltd.

Conditions

Benign Prostatic HyperplasiaLower Urinary Tract Symptoms

Phase 3

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

CompletedNCT01002274

Health Ever Bio-Tech Co., Ltd.Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Start: 2010-08-31End: 2014-06-30Updated: 2016-11-11

Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)

CompletedNCT01002222

Health Ever Bio-Tech Co., Ltd.Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Start: 2011-01-31End: 2014-02-28Target: 200Updated: 2015-03-03

Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms

CompletedNCT01002664

Health Ever Bio-Tech Co., Ltd.Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms

Start: 2010-05-31End: 2014-06-30Updated: 2018-08-02